10-K: BNB Plus Corp. Pivots to Crypto, Reports Wider Loss

BNB Plus Corp. (formerly Applied DNA Sciences, Inc.) has completed a strategic pivot to a digital asset treasury model focused on BNB, while reporting a significantly wider net loss for fiscal year 2025.

Summary

• The company has rebranded from Applied DNA Sciences, Inc. to BNB Plus Corp. and changed its Nasdaq ticker from APDN to BNBX, reflecting a strategic pivot to a digital asset treasury (DAT) model focused on BNB, the native cryptocurrency of the Binance blockchain ecosystem.
• The new strategy involves accumulating BNB and utilizing it to generate yield through staking, restaking, liquid staking, and participation in Binance ecosystem and DeFi opportunities.
• As of December 15, 2025, the company has deployed approximately $3 million to acquire additional BNB tokens at an average price of $895 per token, holding a total of approximately 18,830 BNB through direct holdings and OBNB Trust Units.
• The LineaRx subsidiary, which commercializes nucleic acid production solutions for biopharmaceutical and diagnostics markets, will continue as a secondary business, with R&D efforts now focused solely on optimizing its LineaDNA platform.
• The company reported a net loss of $15,349,246 for the fiscal year ended September 30, 2025, significantly wider than the $7,088,306 net loss in the prior fiscal year.
• Total revenues saw a slight increase to $2,136,935 in FY2025 from $2,113,490 in FY2024, driven by a 33% increase in product revenues, offset by a 31% decrease in service revenues.
• Gross profit decreased by 14% to $838,907 in FY2025, with the gross profit percentage falling from 46% to 39%.
• Research and development expenses increased by 67% to $6,016,912 in FY2025, primarily due to a $2.7 million impairment charge for In Process Research and Development (IPR&D) related to the LineaRNAP enzyme.
• The company completed multiple restructurings, including a cumulative 72% reduction in headcount since January 2025, projected to result in a 70% total reduction in payroll expenses compared to FY2024.
• A Private Placement in October 2025 generated $26.8 million in gross proceeds, with a potential for an additional $30.8 million from warrant exercises, totaling up to $57.6 million in potential gross proceeds.
• The company has mitigated its previously reported substantial doubt about its ability to continue as a going concern, estimating sufficient cash and liquid cryptocurrency to fund operations for the next twelve months.
• A material weakness in internal controls over financial reporting was identified, specifically related to fair value calculations for warrant modifications, for which a remediation plan has been implemented.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the company has secured significant capital and outlined a clear new strategic direction in digital assets, the reported financial results for FY2025 show a substantial increase in net loss and a decline in gross profit. The material weakness in internal controls and the inherent volatility and regulatory uncertainty of the cryptocurrency market introduce significant risks. The strategic pivot is ambitious but unproven, and the write-off of IPR&D in the biotech segment indicates past investment inefficiencies. The capital raise and mitigation of going concern doubt provide a lifeline, but the path to profitability remains highly uncertain and risky.

Positives

• Successfully raised $26.8 million in gross proceeds from a Private Placement in October 2025, with potential for an additional $30.8 million from warrant exercises, significantly improving liquidity.
• Mitigated previously reported substantial doubt about its ability to continue as a going concern, with management estimating sufficient cash and liquid cryptocurrency for the next twelve months.
• Successfully deployed approximately $3 million to acquire additional BNB tokens at an average price of $895 per token, strengthening the new yield-focused BNB treasury strategy.
• Achieved a 33% increase in product revenues in the Therapeutic DNA Production Services segment for FY2025, indicating growth in this core biotech area.
• Implemented significant cost-reduction measures through multiple workforce reductions, resulting in a cumulative 72% headcount reduction and projected 70% payroll expense reduction compared to FY2024.
• Stockholders approved an increase in authorized common stock from 200,000,000 to 500,000,000 and an increase of 5,000,000 shares for the 2020 Equity Incentive Plan, providing flexibility for future capital and compensation.

Negatives

• Reported a significantly wider net loss of $15,349,246 for FY2025, compared to $7,088,306 in FY2024, indicating deteriorating profitability.
• Loss from operations increased by 17% to $16,046,595 in FY2025, reflecting higher operating expenses relative to gross profit.
• Gross profit decreased by 14% and the gross profit percentage declined from 46% to 39% in FY2025, primarily due to a change in product mix and decreased service revenue.
• Research and development expenses increased by 67% in FY2025, largely due to a $2.7 million impairment charge for LineaRNAP IPR&D, indicating a write-down of previously valued assets.
• Cash and cash equivalents decreased significantly to $1,667,800 as of September 30, 2025, from $5,852,363 in the prior year, before the impact of the October 2025 private placement.
• Maintained a negative working capital of $225,485 as of September 30, 2025.
• Identified a material weakness in internal controls over financial reporting related to fair value calculations for warrant modifications, which could impact financial reporting accuracy.
• Experienced multiple Nasdaq minimum bid price deficiencies and reverse stock splits, indicating past struggles with maintaining listing compliance and potential investor confidence issues.

Risks

• Inability to successfully implement the new BNB digital treasury strategy or realize anticipated profitability from yield generation.
• Extreme price volatility of BNB and other cryptocurrencies, which could lead to substantial losses on digital asset holdings and adversely affect the common stock price.
• Regulatory developments related to cryptocurrencies and cryptocurrency markets, including potential classification of BNB as a security, could subject the company to additional regulation, fines, and restrictions.
• Dependence on Binance and its affiliates for the health and credibility of the BNB ecosystem, exposing the company to counterparty, reputational, and regulatory risks outside its control.
• Loss or theft of private keys or breaches of digital wallets could result in the permanent loss of BNB holdings.
• The company has minimal operating history in investing in cryptocurrencies and decentralized finance services, increasing the risk of unsuccessful strategy implementation.
• Reliance on third-party service providers (e.g., Cypress LLC, Cypress Management LLC) for digital asset management, introducing risks of failure, malfeasance, or conflicts of interest.
• Operational risks associated with running validator nodes, secure key management, and slashing protection in a Proof-of-Staked-Authority consensus mechanism.
• Potential for high gas fees on the BNB Chain to decrease investment returns or cause transaction delays.
• The LineaRx business faces extensive competition and risks of technology obsolescence if new products and services are not continually developed and accepted.
• Historical reliance on a small number of customers for a large portion of LineaRx revenues, making the business vulnerable to the loss of any major customer.
• Uncertain U.S. federal, state, local, and non-U.S. income tax treatment of digital assets, which could result in adverse tax consequences.
• Potential for the company to be deemed an investment company under the Investment Company Act, which would impose significant restrictions and make current business impractical.
• Risks related to the potential compromise of blockchain network security by emerging technologies like artificial intelligence and quantum computing.
• The company's concentration in a single digital asset (BNB) exposes it to unique liquidity risks during market stress.
• Instability or failure of other stablecoins could reduce trust in stablecoins the company borrows or invests in, leading to operational and reputational challenges.
• Potential inconsistencies between the stated intentions and future actions of Binance and its related entities regarding BNB trading and burn policies.

Future Outlook

The company projects that its LineaRx subsidiary will significantly narrow its losses in FY26Q1 (ending December 31, 2025) and approach profitability. The primary focus will be on the BNB-focused digital asset treasury strategy, aiming to produce yield through various DeFi opportunities. Future capital expenditures for LineaRx's R&D activities are expected to be less than $70,000 in fiscal 2026, focusing on LineaDNA platform optimization. The company estimates it has sufficient cash and liquid cryptocurrency to fund operations for the next twelve months.

Management Comments

• "We believe our BNB Strategy can produce potential yield via the implementation of one or more of the below strategies: Participation in the Binance Launch Pool, Native Staking on Binance Smart Chain, Liquidity Providing, BNB Collateralization."
• "The Company has mitigated its previously reported substantial doubt of a going concern through the cash received from the Private Placement and the warrant exercises described above."
• "The Company estimates that it will have sufficient cash and cash equivalents, as well as liquid cryptocurrency to fund operations for the next twelve months from the date of filing this annual report."
• "The Company has stopped the further development of the IPR&D, which was the LineaRNAP enzyme, as the Company has determined that further technical development would not yield considerably improved results over the current state of the LineaRNAP technology."

Industry Context

BNB Plus Corp.'s pivot to a digital asset treasury strategy aligns with a growing trend of companies exploring cryptocurrency as a reserve asset and for yield generation, particularly within the decentralized finance (DeFi) space. This move positions the company in a rapidly evolving and highly volatile industry, distinct from its traditional biotech roots. The continued development of the BNB Chain ecosystem, including its various dApps and services, is critical to the company's new model. The biotech segment, LineaRx, operates in the competitive synthetic DNA manufacturing market, which is crucial for advanced biotherapeutics. The company's strategy to potentially sell or license LineaRx technology suggests a focus on monetizing its biotech assets while prioritizing the crypto venture. Regulatory scrutiny on digital assets, as highlighted by the GENIUS Act and CLARITY Act, indicates a maturing but still uncertain regulatory landscape that will significantly shape the industry.

Comparison to Industry Standards

• The company's shift to a digital asset treasury model with a focus on BNB for yield generation is a relatively novel strategy for a publicly traded company, making direct comparisons to established industry standards challenging. Most companies with significant crypto holdings, like MicroStrategy, primarily hold Bitcoin as a reserve asset rather than actively pursuing complex DeFi yield strategies with altcoins like BNB.
• The average acquisition price of approximately $895 per BNB token as of December 15, 2025, can be compared to the market price of BNB at that time to assess the immediate performance of its deployment, though the filing does not provide real-time market data for direct comparison.
• In the Therapeutic DNA Production Services segment, competitors include established players like MilliporeSigma, Aldevron, LLC, and GenScript Biotech Corporation. The company's LineaDNA and LineaIVT platforms aim to offer advantages over traditional plasmid-based DNA manufacturing, such as rapid, cell-free production and reduced impurities, which are competitive differentiators in the biotherapeutics market.
• The reported gross profit percentage of 39% for FY2025 in the context of its biotech operations would need to be benchmarked against the gross margins of its specific competitors in synthetic DNA manufacturing to assess its competitive standing, which is not provided in the filing.
• The significant increase in net loss and accumulated deficit suggests that the company's financial performance, prior to the full implementation of its BNB strategy, has been below industry profitability standards for a growth-oriented company, necessitating the strategic pivot and capital raises.

Management Changes

Corporate Governance

Legal Proceedings

• No material adverse legal proceedings are currently known to be pending against the company.

Related Party Transactions

• Strategic Digital Assets Services Agreement with Cypress LLC (Services Provider) for discretionary asset management of BNB, with Joshua Kruger (Chairman) and Patrick Horsman (CIO) being affiliates of Cypress LLC. Fees include a 1.25% annual management fee and a 10% incentive fee on net returns.
• Strategic Advisor Agreement with Cypress Management LLC (Strategic Advisor) for strategic advice in the crypto technology sector, with Joshua Kruger (Chairman) and Patrick Horsman (CIO) being affiliates of Cypress Management LLC. Fees include a monthly fee of $60,000 and 1,986,634 Advisory Warrants.
• Patrick Horsman, Chief Investment Officer, receives monthly consulting compensation of $29,167 and is a principal of the Patrick Horsman IRA Investment Trust, a purchaser in the Private Placement.
• Consulting Arrangements with Ground Tunnel Capital LLC, including a fee of $1,000,000 and quarterly payments of $250,000 from December 2025 to September 2027, plus Consultant Warrants for 1% of fully diluted equity.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from multiple warrant exercises and future equity issuances. The stock price is highly correlated to BNB volatility. The strategic pivot introduces high-risk, high-reward potential. The material weakness in internal controls could impact confidence in financial reporting.
• **Employees**: Experienced significant workforce reductions (72% cumulative headcount reduction) as part of restructuring, leading to job losses but also a clearer focus for remaining staff on the new BNB strategy and LineaRx.
• **Customers (LineaRx)**: Continued development and commercialization of nucleic acid production solutions, but the company's primary focus has shifted, potentially impacting long-term investment in this segment.
• **Management/Directors**: New employment agreements for CEO and CFO, with performance bonuses tied to strategic transactions. Joshua Kruger and Patrick Horsman, key figures in the new crypto strategy, have significant affiliations with the service providers, raising potential conflicts of interest.

Next Steps

• Actively implement the BNB-focused digital asset treasury strategy, including accumulating BNB tokens and building the necessary operational framework.
• Utilize accumulated BNB for yield generation via Binance native and other decentralized finance opportunities (staking, restaking, liquid staking, Binance Launch Pool, liquidity providing, BNB collateralization).
• Pursue opportunities to sell OBNB Trust Units for cash to purchase additional BNB or access underlying BNB assets.
• Continue to optimize the LineaDNA platform within the LineaRx subsidiary.
• Remediate the identified material weakness in internal controls over financial reporting related to fair value calculations for warrant modifications.
• Record approximately $1.4 million in pre-tax charges related to the October 2025 workforce reduction in the first quarter of fiscal 2026.
• File the Charter Amendment to increase authorized shares of common stock from 200,000,000 to 500,000,000 (decision pending).
• Continue to sell shares under the At The Market Offering Agreement to raise additional capital.

Key Dates

Recommendation

BNB Plus Corp. is undergoing a radical strategic transformation from a biotech company to a digital asset treasury focused on BNB. While the recent capital raise of $26.8 million (with potential for $30.8 million more) provides a much-needed liquidity injection and mitigates immediate going concern doubts, the company's financial performance for FY2025 was poor, with a significantly wider net loss and declining gross profit. The new BNB strategy is high-risk, unproven, and subject to extreme cryptocurrency volatility and evolving regulatory uncertainty, including the potential classification of BNB as a security. The company's reliance on related-party service providers for its crypto operations, coupled with a disclosed material weakness in internal controls, adds layers of governance and operational risk. Given the highly speculative nature of the new business model and the significant uncertainties, a 'hold' recommendation is appropriate. Investors should monitor the execution of the BNB strategy, regulatory developments, and the effectiveness of internal control remediation before considering further investment, while existing shareholders should assess their risk tolerance for this speculative pivot.

Keywords

BNB, Cryptocurrency, Digital Asset Treasury, DeFi, Binance, Blockchain, LineaRx, Synthetic DNA, Biopharmaceuticals, Gene Therapy, mRNA Therapeutics, SEC Filing, 10-K, Financial Reporting, Corporate Restructuring